Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium
Dyne Therapeutics, Inc. (DYN)
Last dyne therapeutics, inc. earnings: 11/1 04:30 pm
Check Earnings Report
US:NYSE Investor Relations:
dynegy.com/investors/presentations-events
Company Research
Source: GlobeNewswire
WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that Wildon Farwell, M.D., MPH, chief medical officer, and Oxana Beskrovnaya, Ph.D., chief scientific officer, are scheduled to participate in a fireside chat during the Cantor Virtual Muscular Dystrophy Symposium on Tuesday, April 2, 2024 at 9:50 a.m. ET. A live webcast will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 days following the presentation. About Dyne Therapeutics Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is
Show less
Read more
Impact Snapshot
Event Time:
DYN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DYN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DYN alerts
High impacting Dyne Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
DYN
News
- SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT [Yahoo! Finance]Yahoo! Finance
- Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer [Yahoo! Finance]Yahoo! Finance
- Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive OfficerGlobeNewswire
- Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium [Yahoo! Finance]Yahoo! Finance
- Dyne Therapeutics, Inc. (NASDAQ: DYN) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $47.00 price target on the stock.MarketBeat
DYN
Earnings
- 3/5/24 - Miss
DYN
Sec Filings
- 4/5/24 - Form ARS
- 4/5/24 - Form DEFA14A
- 4/5/24 - Form DEF
- DYN's page on the SEC website